237 related articles for article (PubMed ID: 21042239)
21. Successful treatment with bortezomib of a refractory humoral rejection of the intestine after multivisceral transplantation.
Island ER; Gonzalez-Pinto IM; Tsai HL; Ruiz P; Tryphonopoulos P; Gonzalez ML; Solano JP; Rossique M; Selvaggi G; Tekin A; Smith LJ; Tzakis AG
Clin Transpl; 2009; ():465-9. PubMed ID: 20524316
[TBL] [Abstract][Full Text] [Related]
22. Bortezomib as a rescue therapy for hyperacute and multi-drug resistant mixed acute rejection after kidney transplantation.
Djamali A; Muth BL; Torrealba J; Bloom D; Miller KM; Lorentzen D; Sollinger HW; Pirsch JD; Mezrich JD
Clin Transpl; 2009; ():485-90. PubMed ID: 20524320
[No Abstract] [Full Text] [Related]
23. Proteasome inhibition for recipient desensitization? A report of two sensitized kidney transplant candidates subjected to bortezomib treatment.
Wahrmann M; Haidinger M; Drach J; Geyeregger R; Kikić Z; Raab R; Säemann MD; Böhmig GA
Clin Transpl; 2009; ():415-20. PubMed ID: 20524307
[TBL] [Abstract][Full Text] [Related]
24. Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition.
Walsh RC; Brailey P; Girnita A; Alloway RR; Shields AR; Wall GE; Sadaka BH; Cardi M; Tevar A; Govil A; Mogilishetty G; Roy-Chaudhury P; Woodle ES
Transplantation; 2011 Jun; 91(11):1218-26. PubMed ID: 21617586
[TBL] [Abstract][Full Text] [Related]
25. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.
Stuckey LJ; Kamoun M; Chan KM
Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499
[TBL] [Abstract][Full Text] [Related]
26. Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection.
Al Meshari K
Clin Transpl; 2009; ():385-6. PubMed ID: 20524302
[No Abstract] [Full Text] [Related]
27. Bortezomib for refractory antibody-mediated cardiac allograft rejection.
Eckman PM; Thorsgard M; Maurer D; Kim Y; Alloway RR; Woodle ES
Clin Transpl; 2009; ():475-8. PubMed ID: 20524318
[TBL] [Abstract][Full Text] [Related]
28. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
Hardinger KL; Murillo D
Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
[TBL] [Abstract][Full Text] [Related]
29. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N
Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274
[TBL] [Abstract][Full Text] [Related]
30. Antihumoral rejection therapy by proteasome inhibitor bortezomib: a case series.
Lachmann N; Schütz M; Budde K; Schönemann C; Waiser J
Clin Transpl; 2009; ():351-8. PubMed ID: 20527073
[TBL] [Abstract][Full Text] [Related]
31. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation.
Patel J; Everly M; Chang D; Kittleson M; Reed E; Kobashigawa J
J Heart Lung Transplant; 2011 Dec; 30(12):1320-6. PubMed ID: 21968130
[TBL] [Abstract][Full Text] [Related]
32. Bortezomib for acute humoral rejection in two repeat transplant recipients.
Hardinger KL; Alford K; Murillo D
Clin Transpl; 2009; ():479-83. PubMed ID: 20524319
[TBL] [Abstract][Full Text] [Related]
33. A summary of bortezomib use in transplantation across 29 centers.
Everly MJ
Clin Transpl; 2009; ():323-37. PubMed ID: 20524294
[TBL] [Abstract][Full Text] [Related]
34. Rescue therapy for acute antibody mediated rejection with a proteosome inhibitor after kidney transplantation.
Manitpisitkul W; Wilson NS; Philosophe B; Cooper M; Drachenberg C; Kukuruga D; Nogueira J; Haririan A
Clin Transpl; 2010; ():421-8. PubMed ID: 21698839
[No Abstract] [Full Text] [Related]
35. Bortezomib as an adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum.
Al Meshari K; Pall A; Elgamal H; Alzayer F; Altalhi M
Clin Transpl; 2010; ():383-90. PubMed ID: 21696055
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line?
Lee I; Constantinescu S; Gillespie A; Swami A; Birkenbach M; Leech S; Silva P; Karachristos A; Daller JA; Sifontis NM
Clin Transpl; 2009; ():425-9. PubMed ID: 20524309
[No Abstract] [Full Text] [Related]
37. Bortezomib use in chronic antibody-mediated allograft dysfunction: updates and additional cases.
Cooper JE; Wiseman AC; Chan L
Clin Transpl; 2010; ():415-20. PubMed ID: 21698838
[No Abstract] [Full Text] [Related]
38. Reduction in proteinuria with bortezomib based therapy for antibody mediated rejection.
Lubetzky M; Auli MJ; Walker J; Leeser D; Kapur S; Hartono C; Dadhania D
Clin Transpl; 2010; ():437-40. PubMed ID: 21696061
[No Abstract] [Full Text] [Related]
39. Antibody-mediated rejection in kidney transplantation: an update.
Lucas JG; Co JP; Nwaogwugwu UT; Dosani I; Sureshkumar KK
Expert Opin Pharmacother; 2011 Mar; 12(4):579-92. PubMed ID: 21294653
[TBL] [Abstract][Full Text] [Related]
40. Bortezomib for antibody mediated rejection treatment: experience at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City.
Leyva S; Marino-Vázquez LA; Reyes-Loaeza JA; Vega O; Uribe-Uribe N; Alberú J; Morales-Buenrostro LE
Clin Transpl; 2009; ():369-76. PubMed ID: 20524300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
